Document Detail

Comparison of the effect of celiprolol and nifedipine on blood pressure and plasma lipids.
MedLine Citation:
PMID:  1381018     Owner:  NLM     Status:  MEDLINE    
During a double-blind, randomized study in hypertensive patients, changes in blood pressure (BP) and in plasma lipid and lipoprotein levels during treatment with celiprolol were compared with those occurring during nifedipine treatment. Fifty-three patients (28 men and 25 women) with mild-to-moderate hypertension, aged 20-64 years, were studied. After a 1-month placebo run-in period, patients were randomly assigned to receive either nifedipine (40 mg daily) or celiprolol (200 mg daily) each time using a double dummy technique. After 6 weeks, dosages of each drug could be doubled. Both drugs caused similar reductions in blood pressure but after 12 weeks treatment, the percentage of decrease in diastolic BP (DBP) was more pronounced (p less than 0.01) in the nifedipine group (-18%) than in the celiprolol group (-12%). After 6 weeks, there were no differences in plasma lipids between the two treatment groups. However, the changes after 12 weeks treatment were different (p less than 0.05) between the groups, leading to lower levels of plasma esterified cholesterol, low-density lipoprotein (LDL) cholesterol and apoprotein AI, AII, and B in the celiprolol group. Plasma lecithin cholesterol acyltransferase activity (LCAT) was not modified, suggesting that reverse cholesterol transport was not affected by the drugs. In both treatment groups, a significant positive relationship was observed between changes in LDL cholesterol and apoprotein B. As compared with nifedipine, celiprolol after 12-week therapy had a rather favorable plasma lipid profile. The clinical relevance of such findings, in terms of prevention of cardiovascular complications, has yet to be established.
R van Hoof; J P Desager; C Harvengt; R Fagard; P Lijnen; P Peerenboom; J Staessen; L Thijs; W Van Mieghem; A Amery
Related Documents :
10372158 - Measurement of leg arterial compliance of normal subjects and diabetics using impedance...
772198 - Reduction of serum cholesterol and blood pressure in hypertensive patients by behaviour...
2783348 - Trends in risk factors for vascular disease in australia.
1770468 - Cross-sectional and longitudinal relationship of sodium-lithium countertransport to ins...
15844018 - Assessing the adequacy of endoscopically tied knots: a functional approach.
16037868 - Hemodynamic performance and incidence of patient-prosthesis mismatch of the complete su...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  20     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1992 Aug 
Date Detail:
Created Date:  1992-10-01     Completed Date:  1992-10-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  268-73     Citation Subset:  IM    
Hypertensie en Cardiovasculaire Revalidatie Eenheid, Katholieke Universiteit Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acyltransferases / blood
Antihypertensive Agents / pharmacology*
Apoproteins / blood
Blood Pressure / drug effects*
Cholesterol / blood
Double-Blind Method
Hypertension / blood,  drug therapy*,  physiopathology
Lipids / blood*
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Middle Aged
Nifedipine / administration & dosage,  pharmacology*
Propanolamines / administration & dosage,  pharmacology*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Apoproteins; 0/Lipids; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Propanolamines; 21829-25-4/Nifedipine; 56980-93-9/Celiprolol; 57-88-5/Cholesterol; EC 2.3.-/Acyltransferases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Profile of cardiovascular effects of NKH477, a novel forskolin derivative, assessed in isolated, blo...
Next Document:  Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alph...